Key clinical point: For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), adding polatuzumab vedotin to bendamustine and rituximab can improve complete response rates and extend overall survival.

Major finding: Patients treated with a combination of polatuzumab vedotin, bendamustine, and rituximab had significantly longer median overall survival than patients who received bendamustine and rituximab (12.4 vs. 4.7 months; P = .002).

Study details: The phase 1b/2 trial involved 107 patients with relapsed/refractory DLBCL.

Disclosures: The study was funded by F. Hoffmann-La Roche and Genentech. The investigators reported additional relationships with AbbVie, Kite Pharma, Lundbeck, and others.